Lipids and compositions for the delivery of therapeutics
The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure wherein: R 1 and R 2 are each independently for each occurrence optionally substituted C 10 -C 30 alkyl, optionally substituted C 10 -C 30 alkenyl, optionally substituted C 10 -C 30 alkynyl, optionally substituted C 10 -C 30 acyl, or -linker-ligand; R 3 is H, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).
1. A lipid particle comprising a lipid and a therapeutic agent, the lipid having the structure
or a salt or isomer thereof,
wherein
E is C(O)O or OC(O);
R 1 and R 2 and R x are each independently for each occurrence H, optionally substituted C 1 -C 10 alkyl, or optionally substituted C 10 -C 30 acyl, provided that at least one of R 1 , R 2 and R x is not H;
R 3 is optionally substituted di(alkyl)aminoalkyl; and
n is 0, 1, 2, or 3.
2. The lipid particle of claim 1 , wherein R 3 is substituted di(alkyl)aminoalkyl.
3. The lipid particle of claim 1 , wherein the term “substituted” refers to the replacement of one or more hydrogen radicals in the structure with the radical of a specified substituent selected from the group consisting of halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, oxo, thioxy, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl, carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, aryl, heteroaryl, heterocyclic, and aliphatic.
4. The lipid particle of claim 3 , wherein the specified substituent is further substituted by replacement of one or more hydrogen radicals in the specified substituent with the radical of a further substituent selected from the group consisting of halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, oxo, thioxy, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl, carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, aryl, heteroaryl, heterocyclic, and aliphatic.
5. The lipid particle of claim 1 , wherein the particle further comprises a neutral lipid and a lipid capable of reducing aggregation.
6. The lipid particle of claim 5 , wherein the neutral lipid is a phospholipid.
7. The lipid particle of claim 5 , wherein the lipid capable of reducing aggregation is a PEG-lipid.
8. The lipid particle of claim 5 , wherein the particle further comprises a sterol.
9. The lipid particle of claim 8 , wherein the sterol is cholesterol.
10. The lipid particle of claim 5 , wherein the therapeutic agent is a nucleic acid.
11. The lipid particle of claim 10 , wherein the nucleic acid is selected from the group consisting of an siRNA and an antisense oligonucleotide.
12. The lipid particle of claim 10 , wherein the nucleic acid is an siRNA.
13. The lipid particle of claim 10 , wherein the nucleic acid is an mRNA.
14. A pharmaceutical composition comprising a lipid particle of claim 1 and a pharmaceutically acceptable excipient, carrier, or diluent.
15. A method of modulating the expression of a target gene in a cell, comprising providing to the cell the lipid particle of claim 1 .
16. A method of modulating the expression of a target gene in a cell, comprising providing to the cell the lipid particle of claim 12 .
17. A method of modulating the expression of a target gene in a cell, comprising providing to the cell the lipid particle of claim 13 .
18. The lipid particle of claim 1 , wherein R 1 and R 2 are each independently C 1 -C 10 alkyl and R x is H.
19. The lipid particle of claim 2 , wherein R 1 and R 2 are each independently C 1 -C 10 alkyl and R x is H.
20. The lipid particle of claim 8 , wherein R 1 and R 2 are each independently C 1 -C 10 alkyl and R x is H.
21. The lipid particle of claim 13 , wherein R 1 and R 2 are each independently C 1 -C 10 alkyl and R x is H.
22. The lipid particle of claim 1 , wherein the therapeutic agent is a nucleic acid.
23. The lipid particle of claim 22 , wherein the nucleic acid is an mRNA.